Featured Alumni

Dr. Steven Mittelman

Dr. Steven Mittelman

Dr. Steven Mittelman is a Visiting Associate Professor of Pediatrics and Chief of the Division of Pediatric Endocrinology at the David Geffen School of Medicine at UCLA. After earning his MD-PhD in at the Keck School of Medicine, he completed both his pediatric residency and pediatric endocrinology fellowship at the Children’s Hospital Los Angeles. At CHLA, Dr. Mittelman was the Director of the Diabetes & Obesity Program, as well as the Donnell Society for Pediatric Scientists. In his current position, Dr. Mittelman is able to devote the majority of his time to his bench and translational research into the associations between obesity and cancer mortality, specifically that of childhood leukemia. He is also involved in a number of other obesity-related research projects, primarily working on understanding the causes and treatments of childhood obesity and how adiposity alters physiology and leads to long-term consequences. His research program is funded by the NIH, and has resulted in over 50 publications. In his administrative role, Dr. Mittelman oversees the research and clinical activities of the Division of Pediatric Endocrinology. He also continues to mentor graduate students, clinical fellows, and junior faculty.
Dr. Devin Wiley

Dr. Devin Wiley

Dr. Devin Wiley (PhD Chemical Engineering, 2013, Caltech; MD, 2015, Keck SOM) is a Co-founder, Chief Medical Officer, and Head of Research and Development at Circumvent Pharmaceuticals. Dr. Wiley helped lead a Caltech-based team in winning the NIH 2015 Neurostartup Challenge that provided seed funding for Circumvent, and he secured additional funding through a 2017 NIH SBIR grant award. At Circumvent, Dr. Wiley manages the discovery, preclinical, and clinical development programs for small molecule Enzyme Replacement Therapies (smERTs) that cross the blood-brain barrier, have minimal toxicity profiles, and that retain activity in treating the ultra-rare and uniformly fatal neurodegenerative disease, Neuronal Ceroid Lipofuscinosis-1 (CLN1 Batten Disease), for which there is currently no therapeutic option. He is charting a path for the development of hydroxylamine-derived smERTs as a new class of therapeutic, with a mission of creating a treatment landscape for CLN1 Batten Disease patients that both extends their lifespan and improves their quality of life.

In addition, Dr. Wiley works as a physician-engineer within the Logic Technology Development (LTD) division of Intel, and he serves on Intel’s Clinical Advisory Board. With in LTD, Dr. Wiley engineers next generation Intel Microchip technologies. Within the Clinical Advisory Board he contributes to high-level, clinically-related corporate strategy discussions that are focused on Intel’s current and future market positions within healthcare.